Real world studies in infrequently exacerbating patients with COPD

Brian Lipworth (Lead / Corresponding author), Chris Kuo

Research output: Contribution to journalLetter

Abstract

The benefits of inhaled corticosteroids (ICS) as dual- or triple-combination therapy are more pronounced in patients with the frequent exacerbating eosinophilic (FEE) phenotype of COPD, corresponding to Global Initiative for Chronic Obstructive Lung Disease (GOLD) group D.1 In the June issue of CHEST, the real-life study by Suissa et al2 looks at a cohort of patients with COPD in whom 82% had zero or one prior exacerbation, corresponding to GOLD group B. In infrequently exacerbating patients one might expect there to be little impact conferred by using an ICS in combination with a long-acting β-agonist (LABA).
Original languageEnglish
Pages (from-to)415-416
Number of pages2
JournalChest
Volume156
Issue number2
DOIs
Publication statusPublished - Aug 2019

Fingerprint

Chronic Obstructive Pulmonary Disease
Adrenal Cortex Hormones
Phenotype
Therapeutics

Keywords

  • COPD
  • Inhaled corticosteroids
  • Long acting bronchodilators

Cite this

@article{de8380d85ddd45159055b579a6c7afd5,
title = "Real world studies in infrequently exacerbating patients with COPD",
abstract = "The benefits of inhaled corticosteroids (ICS) as dual- or triple-combination therapy are more pronounced in patients with the frequent exacerbating eosinophilic (FEE) phenotype of COPD, corresponding to Global Initiative for Chronic Obstructive Lung Disease (GOLD) group D.1 In the June issue of CHEST, the real-life study by Suissa et al2 looks at a cohort of patients with COPD in whom 82{\%} had zero or one prior exacerbation, corresponding to GOLD group B. In infrequently exacerbating patients one might expect there to be little impact conferred by using an ICS in combination with a long-acting β-agonist (LABA).",
keywords = "COPD, Inhaled corticosteroids, Long acting bronchodilators",
author = "Brian Lipworth and Chris Kuo",
year = "2019",
month = "8",
doi = "10.1016/j.chest.2019.04.094",
language = "English",
volume = "156",
pages = "415--416",
journal = "Chest",
issn = "0012-3692",
publisher = "Elsevier",
number = "2",

}

Real world studies in infrequently exacerbating patients with COPD. / Lipworth, Brian (Lead / Corresponding author); Kuo, Chris.

In: Chest, Vol. 156, No. 2, 08.2019, p. 415-416.

Research output: Contribution to journalLetter

TY - JOUR

T1 - Real world studies in infrequently exacerbating patients with COPD

AU - Lipworth, Brian

AU - Kuo, Chris

PY - 2019/8

Y1 - 2019/8

N2 - The benefits of inhaled corticosteroids (ICS) as dual- or triple-combination therapy are more pronounced in patients with the frequent exacerbating eosinophilic (FEE) phenotype of COPD, corresponding to Global Initiative for Chronic Obstructive Lung Disease (GOLD) group D.1 In the June issue of CHEST, the real-life study by Suissa et al2 looks at a cohort of patients with COPD in whom 82% had zero or one prior exacerbation, corresponding to GOLD group B. In infrequently exacerbating patients one might expect there to be little impact conferred by using an ICS in combination with a long-acting β-agonist (LABA).

AB - The benefits of inhaled corticosteroids (ICS) as dual- or triple-combination therapy are more pronounced in patients with the frequent exacerbating eosinophilic (FEE) phenotype of COPD, corresponding to Global Initiative for Chronic Obstructive Lung Disease (GOLD) group D.1 In the June issue of CHEST, the real-life study by Suissa et al2 looks at a cohort of patients with COPD in whom 82% had zero or one prior exacerbation, corresponding to GOLD group B. In infrequently exacerbating patients one might expect there to be little impact conferred by using an ICS in combination with a long-acting β-agonist (LABA).

KW - COPD

KW - Inhaled corticosteroids

KW - Long acting bronchodilators

UR - http://www.scopus.com/inward/record.url?scp=85069690041&partnerID=8YFLogxK

U2 - 10.1016/j.chest.2019.04.094

DO - 10.1016/j.chest.2019.04.094

M3 - Letter

C2 - 31395260

VL - 156

SP - 415

EP - 416

JO - Chest

JF - Chest

SN - 0012-3692

IS - 2

ER -